Get the Stockscreener App
23.67
0.04%
0.01
After Hours:
23.67
Assembly Biosciences Inc stock is traded at $23.67, with a volume of 143.52K.
It is up +0.04% in the last 24 hours and down -33.00% over the past month.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
See More
Previous Close:
$23.66
Open:
$23.7
24h Volume:
143.52K
Relative Volume:
0.49
Market Cap:
$481.94M
Revenue:
$71.10M
Net Income/Loss:
$-6.38M
P/E Ratio:
-19.71
EPS:
-1.2009
Net Cash Flow:
$-39.84M
1W Performance:
-5.21%
1M Performance:
-33.00%
6M Performance:
-17.44%
1Y Performance:
-7.29%
1-Day Range:
$23.43
$24.25
1-Week Range:
$23.15
$25.89
52-Week Range:
$21.80
$39.70
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences Inc
Sector
Industry
Phone
(833) 409-4583
Address
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
23.67 | 481.94M | 71.10M | -6.38M | -39.84M | -1.2009 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Guggenheim | Buy |
| Sep-20-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Neutral |
| Sep-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-19-20 | Initiated | Truist | Buy |
| Oct-16-19 | Initiated | Mizuho | Buy |
| Nov-19-18 | Initiated | Leerink Partners | Outperform |
| Oct-08-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Aug-08-18 | Initiated | Robert W. Baird | Outperform |
| Apr-13-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Nov-08-17 | Initiated | Jefferies | Buy |
| May-30-17 | Initiated | Chardan Capital Markets | Buy |
View All
Assembly Biosciences Inc Stock (ASMB) Latest News
(ASMB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Assembly Biosciences, Inc.(NasdaqGS:ASMB) added to S&P Biotechnology Select Industry Index - marketscreener.com
Best Momentum Stocks to Buy for September 17th - The Globe and Mail
New Strong Buy Stocks for September 17th - The Globe and Mail
Understanding Momentum Shifts in (ASMB) - Stock Traders Daily
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference - manilatimes.net
Assembly Bio schedules a live webcast for Sept. 16 - Stock Titan
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks - TradingView
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program - manilatimes.net
Why is Assembly Biosciences stock surging today? By Investing.com - Investing.com Australia
Assembly Bio opts into 40% U.S. profit share for herpes drug By Investing.com - Investing.com South Africa
Why is Assembly Biosciences stock surging today? - Investing.com
Assembly Biosciences (ASMB) Shares U.S. Development Costs and Profits with Gilead on Herpes Treatment - GuruFocus
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com South Africa
Assembly Bio stock gains after exercising Gilead profit option - investing.com
Assembly Bio opts into 40% U.S. profit share for herpes drug - Investing.com Canada
Assembly Biosciences exercises profit share option with Gilead for HSV program - TipRanks
A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan
Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services - Yahoo Finance
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High? - Yahoo Finance
Assembly Biosciences Price Target Announced at $52.00/Share by UBS - Moomoo
Should You Buy Assembly Biosciences (ASMB) After Golden Cross? - Yahoo Finance
How Assembly Biosciences Inc. (ASMB) Affects Rotational Strategy Timing - Stock Traders Daily
Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Assembly Biosciences (ASMB) - The Globe and Mail
ASMB Maintained by Mizuho -- Price Target Lowered to $45 - GuruFocus
ASMB Initiates Coverage On UBS -- Price Target Announced at $52. - GuruFocus
Assembly Biosciences price target raised to $53 from $45 at Mizuho - TipRanks
UBS initiates Assembly Biosciences stock with buy rating on antiviral platform - Investing.com Nigeria
UBS initiates Assembly Biosciences stock with buy rating on antiviral platform By Investing.com - Investing.com South Africa
Mizuho lowers Assembly Biosciences stock price target to $45 - Investing.com
Assembly Biosciences Inc (ASMB) Stock Price, Quote, News & History - Benzinga
Price to earnings forward of Assembly Biosciences, Inc. – NASDAQ:ASMB - TradingView
Certain Stock Options of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. - marketscreener.com
Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet - Zacks Investment Research
Q3 EPS Forecast for Assembly Biosciences Raised by Analyst - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Shares Gap UpShould You Buy? - MarketBeat
HC Wainwright Issues Negative Estimate for ASMB Earnings - MarketBeat
Assembly Biosciences (ASMB) Slides 8.92% to $30.01 as Key Support Comes into FocusFundamental Weighted - vinanet.vn
Assembly Biosciences (NASDAQ:ASMB) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Assembly Biosciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Assembly Biosciences stock rating at buy By Investing.com - Investing.com India
ASMB Reiterated by HC Wainwright & Co. -- Maintains Price Target at $50 - GuruFocus
Assembly Biosciences reports Q2 EPS (20c), consensus (52c) - TipRanks
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal - Seeking Alpha
Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Assembly Biosciences (ASMB) sees Paradigm BioCapital report 7.8% ownership stake - Stock Titan
Why (ASMB) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Assembly Biosciences (NASDAQ:ASMB) Trading Up 8.2% on Strong Earnings - MarketBeat
Assembly Biosciences, Inc.: Revenue and Earnings Analysts Forecasts Revisions | ASMB | US0453962070 - marketscreener.com
Assembly Biosciences earnings beat by $0.53, revenue topped estimates - Investing.com Nigeria
Assembly Biosciences Inc Stock (ASMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):